MGNX (Macrogenics) Inventories, Other : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Macrogenics's other inventories for the quarter that ended in Sep. 2024 was $0.0 Mil.

Macrogenics's quarterly other inventories stayed the same from Mar. 2024 ($0.0 Mil) to Jun. 2024 ($0.0 Mil) but then increased from Jun. 2024 ($0.0 Mil) to Sep. 2024 ($0.0 Mil).

Macrogenics Inventories, Other Historical Data

The historical data trend for Macrogenics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Inventories, Other Chart

Macrogenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Other

Get a 7-Day Free Trial

Macrogenics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Other	Get a 7-Day Free Trial															-	-	-	-	-

Macrogenics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

M55:Germany

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Executives

Jeffrey Stuart Peters	officer: Acting General Counsel	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
James Karrels	officer: SVP, CFO and Secretary	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Thomas Spitznagel	officer: Sr VP, BPD & Manufacturing	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Eric Blasius Risser	officer: Sr VP & Chief Business Officer	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Ezio Bonvini	officer: Sr VP, Research & CSO	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz	director
Margaret Liu	director	C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kenneth Galbraith	director	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck	officer: Chief Medical Officer	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949